Evofem Biosciences, Inc. Share Price

Equities

EVFM

US30048L3024

Pharmaceuticals

Market Closed - OTC Markets 01:28:42 27/04/2024 am IST 5-day change 1st Jan Change
0.0168 USD +17.96% Intraday chart for Evofem Biosciences, Inc. +9.09% -73.75%
Sales 2022 16.84 1.4K Sales 2023 18.22 1.52K Capitalization 1.28M 107M
Net income 2022 -76M -6.34B Net income 2023 53M 4.42B EV / Sales 2022 45,28,434 x
Net Debt 2022 68.36M 5.7B Net Debt 2023 43.37M 3.62B EV / Sales 2023 24,51,077 x
P/E ratio 2022
-0.05 x
P/E ratio 2023
1.2 x
Employees 38
Yield 2022 *
-
Yield 2023
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Evofem Biosciences, Inc.

1 day+17.96%
1 week+9.09%
Current month-30.29%
1 month-7.69%
3 months-51.86%
6 months-79.78%
Current year-73.75%
More quotes
1 week
0.01
Extreme 0.0125
0.02
1 month
0.01
Extreme 0.0125
0.03
Current year
0.01
Extreme 0.0122
0.06
1 year
0.01
Extreme 0.0122
3.75
3 years
0.01
Extreme 0.0122
2 887.50
5 years
0.01
Extreme 0.0122
14 062.49
10 years
0.01
Extreme 0.0122
23 549.99
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 01/13/01
Director of Finance/CFO 46 01/18/01
Investor Relations Contact - 01/18/01
Members of the board TitleAgeSince
Chief Executive Officer 54 01/13/01
Director/Board Member 56 01/18/01
Director/Board Member 65 01/18/01
More insiders
Date Price Change Volume
26/24/26 0.0168 +17.96% 555,899
25/24/25 0.0142 -4.70% 178,028
24/24/24 0.0149 +16.04% 740,620
23/24/23 0.0128 -19.25% 1,921,977
22/24/22 0.0159 +3.25% 157,974

Delayed Quote OTC Markets, April 27, 2024 at 01:28 am IST

More quotes
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing advanced products to address unmet needs in women’s sexual and reproductive health. The Company’s first FDA-approved product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Phexxi is an advanced gel that works to prevent pregnancy without the use of hormones. Phexxi prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Phexxi is designed to address underserved and unmet needs in the birth control market. Additionally, the Company offers women direct access to Phexxi through its telehealth partner. Using this platform, women can have a telehealth visit with a health care provider (HCP) to determine their eligibility for a Phexxi prescription.
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.0168
Average target price
-
Consensus